Browse the evidence

Mechanical unloading (disuse) induces skeletal muscle atrophy primarily through a dual mechanism: suppression of the IGF-1-Akt-mTOR protein synthesis pathway and upregulation of the ubiquitin-proteasome system (specifically MuRF1/MAFbx E3 ligases) driven by FOXO transcription factors.

If you are experiencing forced inactivity (like casting or bed rest), your muscles will shrink due to suppressed growth signals (mTOR) and increased breakdown signals (FOXO/MuRF1). While you cannot fully stop this, engaging in any available resistance exercise (even isometric) or ensuring adequate protein intake may help mitigate the rate of loss by keeping these pathways partially active.

Oxidative stress (ROS overproduction) and Calcium (Ca2+) overload are major triggers that exacerbate disuse-induced muscle atrophy by promoting protein breakdown and inhibiting synthesis.

Managing oxidative stress and calcium handling may help protect muscle during periods of inactivity. Antioxidants and strategies to maintain muscle membrane integrity might be beneficial, though the paper notes these are 'potential countermeasures' requiring more research.

Short-term administration of high-dose intramuscular testosterone esters in older men (age >60) significantly worsens sleep architecture and breathing by reducing total sleep time and increasing respiratory disturbance indices and hypoxemia duration.

If you are an older man considering high-dose testosterone therapy, be aware that it can significantly reduce your total sleep time and worsen breathing during sleep (increasing apnea events). While this short-term high-dose study did not show immediate negative effects on physical or mental function, the sleep disruption is a significant safety concern that warrants monitoring, especially if you have risk factors for sleep apnea.

Central nervous system (CNS) action of leptin and insulin is essential for maintaining body weight and fuel metabolism, with hypothalamic neurons (specifically POMC and AGRP/NPY populations) serving as primary mediators of their anorexigenic effects.

Your brain's ability to process signals from fat (leptin) and blood sugar (insulin) is the primary switch for hunger and energy use. In obesity, this switch gets stuck, making weight loss difficult despite high hormone levels. Restoring sensitivity to these signals is key to regulating energy homeostasis.

CNS insulin signaling regulates systemic glucose homeostasis primarily through POMC neurons, whereas its effect on body weight involves additional, less-defined neuronal populations.

Insulin's effect on blood sugar regulation is tightly linked to specific brain neurons (POMC), while its effect on weight involves a broader network. This explains why treating insulin resistance might improve blood sugar control differently than it affects body weight.

Obesity-induced CNS insulin and leptin resistance is driven by impaired blood-brain barrier transport, chronic low-grade inflammation (TNF-alpha, IL-6), and upregulation of negative regulators like SOCS3 and PTP1B.

In obesity, the brain stops listening to leptin and insulin due to inflammation and transport issues. This resistance is a key barrier to weight loss. Addressing inflammation and improving metabolic health may help restore the brain's ability to regulate weight.

Brown adipose tissue (BAT) activity in adult humans exhibits strong seasonal variation, with prevalence and intensity significantly higher in winter compared to summer, and this variation is more closely associated with photoperiod (night length) than ambient temperature.

Your body's fat-burning tissue (BAT) naturally fluctuates with the seasons, peaking in winter. This is driven more by day length than just cold exposure. Do not expect your metabolic rate to be identical year-round; however, this variation does not negate the importance of consistent healthy habits. If you are using cold exposure or other BAT-stimulating strategies, expect them to be more effective in colder months or shorter days.

Female adults have a significantly higher prevalence of brown adipose tissue (BAT) activity compared to male adults.

Women are more likely to have active brown fat than men. This biological difference may contribute to variations in metabolic rate and fat handling between sexes. It does not mean men cannot benefit from BAT activation, but the baseline prevalence is lower.

Maternal obesity and gestational diabetes significantly increase the risk of offspring obesity and type 2 diabetes, primarily through excess fetal adiposity and subsequent postnatal catch-up growth.

If you are obese or have gestational diabetes, be aware that your child is at higher risk for obesity and type 2 diabetes. Focus on healthy lifestyle choices for the whole family, including balanced diet and physical activity, and monitor your child's weight gain closely.

Premenopausal women exhibit higher insulin-stimulated glucose uptake in skeletal muscle compared to men, a difference mediated by estradiol signaling and higher adiponectin levels.

If you are a healthy premenopausal woman, your body is biologically wired to handle insulin and glucose more efficiently in your muscles than a man's, largely due to estrogen. This is a protective factor against type 2 diabetes, but it does not negate the importance of maintaining muscle mass and fitness.

Use of oral contraceptives (OC) containing ethinyl estradiol significantly reduces whole-body insulin sensitivity in young healthy women.

If you take birth control pills, be aware that the estrogen in them can make your body less sensitive to insulin by about 40% compared to women not on pills. This doesn't mean you will get diabetes, but it is a factor to consider if you have other risk factors.

Women have higher skeletal muscle lipoprotein lipase (mLPL) mRNA expression and higher plasma triglyceride clearance compared to men, facilitating greater lipid storage in muscle.

Women's bodies are biologically designed to clear fats from the blood into muscle more efficiently than men's. This is why women often have lower post-meal triglyceride levels, which is a protective factor for heart health.

GLP-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects by suppressing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and inhibiting the NF-κB pathway, independent of glycemic control.

GLP-1 medications like semaglutide and liraglutide do more than just lower blood sugar; they actively reduce systemic inflammation by blocking key inflammatory pathways (NF-κB) and lowering pro-inflammatory cytokines. This benefit exists regardless of whether your blood sugar improves, suggesting these drugs may help with inflammatory conditions beyond diabetes.

Obesity induces low-grade chronic inflammation in white adipose tissue (WAT) via adipocyte death (apoptosis/necroptosis), which recruits pro-inflammatory macrophages (forming crown-like structures) and triggers systemic insulin resistance and metabolic syndrome.

Obesity is not just about storing fat; it is an active inflammatory state. Excess fat, especially visceral fat, leads to adipocyte death, which triggers an immune response (inflammation) that blocks insulin signaling. To improve metabolic health, strategies must address this underlying inflammation, not just caloric intake, by supporting adipose tissue health and reducing cytokine-driven resistance.

TNF and NF-κB signaling pathways directly inhibit insulin signaling by phosphorylating IRS-1, thereby causing insulin resistance; neutralizing TNF or inhibiting IKKβ improves glucose homeostasis.

Chronic inflammation in fat tissue directly blocks insulin's ability to work by interfering with key signaling proteins (IRS-1). Reducing this inflammation, whether through weight loss, exercise, or potentially anti-inflammatory strategies, can restore insulin sensitivity.

Nitric oxide (NO) bioavailability is significantly diminished in states of obesity and insulin resistance due to reduced NOS3 expression, impaired NOS3 activity, and increased NO quenching by reactive oxygen species.

If you have obesity or insulin resistance, your body's natural nitric oxide signaling is likely impaired, contributing to fat storage and metabolic issues. This isn't just about willpower; it's a molecular dysfunction. Strategies that support endothelial health and NO production (like exercise, which increases shear stress on blood vessels) may help restore this regulation.

Glycemic index does not significantly alter blood glucose or insulin levels during high-intensity exercise, despite differences in the postprandial period.

You do not need to worry about your pre-workout meal causing a blood sugar crash during high-intensity exercise. This study found that blood glucose levels were the same whether you ate a high or low glycemic meal 90 minutes prior. Focus on getting enough carbohydrates overall rather than stressing over the glycemic index.

Slow-wave sleep (N3 stage) is the primary driver of glymphatic clearance, facilitating the removal of neurotoxic waste products like amyloid-beta and tau from the brain.

Prioritize getting enough slow-wave sleep (deep sleep) to allow your brain to clear out metabolic waste like amyloid-beta. This happens naturally during the N3 stage of sleep. Protecting this sleep phase is a critical preventative measure against neurodegenerative diseases like Alzheimer's.

During the menopausal transition, the accumulation of intraabdominal fat (IAF) is associated with a deleterious shift in adipokine and inflammatory profiles, specifically characterized by increased levels of leptin, tissue plasminogen activator (tPA), serum amyloid A (SAA), and C-reactive protein (CRP), alongside a negative correlation with adiponectin.

For women undergoing menopause, monitor waist circumference and visceral fat rather than just total body weight. Even if your overall weight remains stable, the shift of fat to the abdominal area can trigger inflammatory changes (like increased CRP and leptin) that increase cardiovascular risk. Prioritize strategies that preserve or reduce visceral fat, such as resistance training and managing stress, as these hormonal shifts are a key driver of postmenopausal metabolic health.

PPARγ activation in macrophages promotes cholesterol efflux via the LXR-ABCA1 pathway, resulting in a net anti-atherogenic effect despite simultaneously increasing lipid uptake receptors like CD36.

PPARγ-activating drugs help reduce cardiovascular risk in diabetics by helping macrophages remove cholesterol from artery walls, which outweighs any increase in lipid uptake.

Obesity-induced adipose tissue fibrosis, driven by unresolved inflammation and hypoxia, restricts adipose expandability and contributes to insulin resistance and resistance to weight loss.

Focus on preventing fat tissue damage (fibrosis) rather than just losing weight. Strategies that reduce inflammation and improve vascularization in fat tissue may be more metabolically beneficial than weight loss alone, especially in severe obesity.

Promoting angiogenesis (healthy vascularization) in adipose tissue reduces inflammation and fibrosis, whereas suboptimal vascularization leads to hypoxia and insulin resistance.

Maintaining good blood flow to fat tissue through exercise and healthy lifestyle may help prevent the stiffening (fibrosis) of fat tissue, which is linked to insulin resistance.

Bariatric surgery-induced weight loss does not resolve adipose tissue fibrosis and may even increase ECM deposition, potentially contributing to metabolic deterioration during weight rebound.

Weight loss surgery reduces fat mass but may leave fat tissue stiff and inflamed. Long-term management should focus on maintaining metabolic health, not just weight loss, to mitigate fibrosis-related risks.

Exogenous leptin administration fails to produce significant weight loss in individuals with common obesity due to central leptin resistance, despite being effective in treating congenital leptin deficiency.

Taking leptin supplements or relying on high-leptin foods will not help you lose weight if you have common obesity. Your body already produces high levels of leptin but has become resistant to its signals. Effective treatment requires addressing this resistance, not just adding more hormone.